Peptide-based Delivery Platform

Peptide-based Delivery Platform

Our peptide-based delivery platform is an integrated technology suite designed to solve one of the most critical challenges in modern therapeutics—how to safely and precisely deliver genetic medicines, proteins, and small molecules to the right cells. By combining programmable peptide engineering, modular delivery architectures, and advanced formulation capabilities, we provide end-to-end solutions that enable high-efficiency intracellular delivery, tissue-specific targeting, and superior manufacturability. Our platform supports a full spectrum of therapeutic modalities—including mRNA, siRNA, ASO, CRISPR RNPs, biologics, and small molecules—offering researchers and developers a powerful, non-viral alternative for next-generation drug development.

What Are Peptide-Based Delivery Systems?

Peptide-based delivery systems are engineered therapeutic carriers composed of short, programmable amino-acid sequences purpose-built to transport genetic medicines, proteins, and small molecules across biological barriers. Unlike viral vectors or conventional lipid nanoparticles, peptide delivery systems leverage intrinsic biological functions—cell penetration, receptor targeting, membrane fusion, and self-assembly—to achieve highly specific and efficient payload delivery.

These systems can be rationally designed to:

Bind and transport nucleic acids (mRNA, siRNA, ASO, CRISPR RNP)

Deliver functional proteins or enzymes directly to the cytosol

Penetrate hard-to-reach tissues, including tumor microenvironments and the central nervous system

Exhibit superior stability and manufacturability, thanks to the chemical scalability of peptides

Minimize immunogenicity and off-target effects through precision targeting and controlled release

As a fully programmable, non-viral modality, peptide-based delivery enables next-generation therapeutics that require precision, modularity, and safety—unlocking indications inaccessible to traditional delivery systems.

Platform Value: Why Peptide Delivery Matters

Our peptide-based delivery platform is designed to address the fundamental challenge of modern therapeutics: achieving safe, efficient, and precise delivery of complex modalities to the right cells and tissues. By integrating modular peptide engineering, programmable design principles, and scalable formulation strategies, our platform enables tailored delivery solutions across genetic medicines, biologics, and small-molecule therapeutics. This approach provides a flexible, non-viral alternative to conventional delivery systems while supporting rapid development and clinical translation.

Our platform creates a versatile, programmable delivery foundation that unlocks new therapeutic possibilities while reducing development risk and accelerating timelines.

Modular Platform Design: Interchangeable peptide modules enable rapid customization of delivery systems to match specific payloads, targets, and disease biology.

Programmable Peptide Engineering: Rational and AI-assisted peptide design allows precise tuning of stability, targeting, intracellular trafficking, and manufacturability.

Broad Modality Compatibility: A single delivery platform supports mRNA, siRNA, ASO, CRISPR cargos, proteins, and small molecules without fundamental redesign.

Precision Tissue Targeting: Targeting peptides enable organ- and cell-specific delivery, improving therapeutic index and minimizing systemic toxicity.

Efficient Intracellular Delivery: Optimized CPP and fusogenic peptide systems enhance cellular uptake and endosomal escape for improved functional efficacy.

Scalable Manufacturing Readiness: Fully synthetic, chemically defined peptide systems offer predictable quality, reproducibility, and seamless transition toward GMP production.

Modular Peptide Delivery Platform

Our peptide-based delivery platform is built around six synergistic technology modules. Each module offers specialized capabilities and can be combined to create a fully customized delivery system tailored to the biology of each disease and the requirements of each therapeutic payload.

CPP-based Delivery Platform

Cell-penetrating peptides (CPPs) designed for rapid membrane translocation and cytosolic delivery.

Service Capabilities

Custom CPP discovery, optimization & engineering

Charge, amphiphilicity & hydrophobicity tuning

CPP–cargo conjugation and complexation strategies

Stability, uptake, and intracellular trafficking studies

in vitro and in vivo delivery performance evaluation

Deliverable Payload Types

Nucleic acids: mRNA, saRNA, siRNA, ASO, DNA, CRISPR RNPs

Proteins & biologics: enzymes, peptides, antibody fragments

Small molecules requiring intracellular entry

Endosomal Escape & Fusogenic Peptide Platform

Membrane-active peptides enabling efficient release of therapeutic cargos from endosomes into the cytosol.

Design of pH-responsive & fusogenic peptides

Engineering of HA2-, KALA-, and INF7-like sequences

Endosomal escape optimization

Mechanistic validation via imaging and quantification assays

Integration into CPP, LNP, polymer, or hybrid systems

mRNA / saRNA

siRNA / ASO

CRISPR-Cas RNP complexes

Protein and enzyme therapeutics

Targeted Peptide Delivery Platform

Receptor-specific and tissue-targeting peptides for organ- and cell-type–precise delivery.

Targeting peptide discovery via phage or mRNA display

Design of BBB shuttles, tumor-penetrating and immune-cell targeting peptides

Peptide-nanoparticle surface functionalization

Receptor binding and targeting validation

in vivo biodistribution and organ-targeting studies

mRNA, siRNA, ASO, CRISPR genetic medicines

Proteins, cytokines, and enzymes

Small molecules for tissue- or tumor-specific targeting

Self-Assembling Peptide Nanoparticle (SAPN) Platform

Peptides that self-assemble into nanostructures capable of encapsulating and protecting diverse therapeutic cargos.

De novo SAPN design (β-sheet, α-helix, coiled-coil)

Optimization of particle size, morphology, and stability

Encapsulation of nucleic acids or proteins

Serum stability, release kinetics, and structural characterization

Scalable formulation development

siRNA / ASO / DNA

CRISPR RNP

Proteins, peptides, and small molecules

Peptide-Lipid Hybrid LNP Platform

Next-generation lipid nanoparticles enhanced with peptides for improved targeting and intracellular delivery.

Incorporation of CPPs, targeting, or fusogenic peptides into LNPs

Peptide–lipid conjugate synthesis

Optimization of stability, encapsulation efficiency, and biodistribution

in vitro and in vivo functional testing

Endosomal escape–enhanced LNP engineering

CRISPR components

Peptide–drug conjugates

Peptide-Polymer Hybrid Delivery Platform

Polymer–peptide hybrid carriers offering enhanced stability, controlled release, and tunable pharmacokinetics.

Design and synthesis of peptide–polymer conjugates

Formulation of micelles, hydrogels, and nanoparticles

Controlled-release system engineering

Stability, diffusion, and release profiling

Custom hybrid platform development for specific indications

Small molecules (long-acting formulations)

Proteins and peptides

siRNA / DNA / ASO

mRNA (select polymer systems)

Delivery Platform Module Overview

This table summarizes the six core peptide-based delivery modules within our platform, highlighting their primary mechanisms, compatible payloads, and key advantages. Together, these modules form a flexible, modular delivery framework that can be configured to meet diverse therapeutic needs.

CPP-Based Delivery

Direct membrane penetration

mRNA, siRNA, ASO, CRISPR RNP, proteins, small molecules

Fast cytosolic entry, high versatility

Fusogenic/Endosomal Escape Peptides

pH-triggered membrane disruption

RNA therapeutics, CRISPR, proteins

Strong endosomal escape efficiency

Targeted Peptide Delivery

Receptor-specific binding

All payload types

Organ/cell-type specificity, reduced toxicity

SAPN (Self-Assembling Peptide Nanoparticles)

Nanostructure self-assembly

RNA, proteins, small molecules

Tunable structure, high stability

Peptide-Lipid Hybrid LNP

LNP enhanced with peptides

mRNA, siRNA, CRISPR

Improved targeting & intracellular delivery

Peptide-Polymer Hybrid Systems

Polymer-peptide conjugates

Proteins, small molecules, RNA

Controlled release, long-acting formulations

Payload Compatibility Matrix

This matrix illustrates the compatibility between different therapeutic payload types and each delivery module, providing a clear view of how our peptide-based technologies support multiple modalities. It highlights the versatility of the platform across RNA therapeutics, gene editing, biologics, and small-molecule delivery.

mRNA / saRNA

✓✓✓

✓✓

✓

siRNA / ASO

CRISPR RNP

–

Proteins / Enzymes

Antibody Fragments / Intrabodies

Peptides / Peptide Therapeutics

Small Molecules

Combination Payloads

Legend: ✓= compatible ✓✓= high compatibility ✓✓✓= optimal

Technology Capabilities

Our integrated technology stack spans the entire pipeline—from design to in vivo validation.

Peptide Discovery & Screening

AI-driven peptide sequence design

Phage display and mRNA display (RaPID)

High-throughput peptide library generation

Mechanistic screening for cell penetration, receptor binding, and membrane fusion

Peptide Engineering & Optimization

Sequence optimization of charge, amphiphilicity, and hydrophobicity

Cyclization, D-amino acid incorporation, and backbone stabilization

Enzyme-responsive and pH-responsive peptide linkers

Conjugation chemistries for nucleic acids, proteins, and small molecules

Assembly & Formulation

Self-assembling peptide nanoparticles (SAPNs)

Peptide–lipid hybrid LNP formulation

Peptide–polymer nanoparticle fabrication

Peptide–drug conjugates (PDCs)

Encapsulation and complexation optimization for mRNA, siRNA, and CRISPR cargos

in vitro Evaluation Platform

Cellular uptake assays

Endosomal escape quantification

Transfection efficiency evaluation

Target binding and receptor engagement studies

Cytotoxicity, hemolysis, and serum stability assays

in vivo Validation

Biodistribution and organ-targeting analysis

Pharmacokinetics (PK) and pharmacodynamics (PD) modeling

mRNA expression and gene-silencing studies

Tumor penetration and CNS delivery assessment

Immunogenicity and safety profiling

Why Partner With Us?

Modular Platform Design

Our peptide delivery platform enables rapid customization and seamless assembly of delivery modules tailored to each therapeutic program.

Broad Payload Compatibility

A single, unified system supports RNA therapeutics, gene-editing cargos, proteins, and small molecules across multiple modalities.

Precision Tissue Targeting

Engineered targeting peptides enable organ- and cell-specific delivery while minimizing off-target exposure.

Efficient Intracellular Delivery

Optimized cell-penetrating and fusogenic peptides maximize cytosolic delivery and functional therapeutic outcomes.

Scalable Manufacturing Readiness

Chemically defined peptide systems support robust scale-up and smooth transition toward GMP production.

Flexible Partnership Models

We offer custom development, co-development, and platform licensing options aligned with your scientific and IP strategy.

How We Work

A structured, milestone-driven process designed to accelerate delivery system development while maintaining scientific rigor and operational clarity.

1

Project Consultation & Requirement Mapping

Understand therapeutic modality (mRNA, siRNA, CRISPR, protein, small molecule)

Define delivery challenges and target tissues

Clarify project scope, delivery goals, timelines, and IP arrangements

2

Peptide Module Selection & Preliminary Design

Select CPP, targeting, fusogenic, or SAPN modules

AI-assisted peptide design and sequence optimization

Preliminary design report for client approval

3

Custom Engineering & Formulation Development

Synthesis of peptides and peptide conjugates

Assembly of nanoparticle or hybrid delivery systems

Optimization of encapsulation, stability, targeting, and pharmacokinetics

4

in vitro Evaluation

Cellular uptake assessment

Endosomal escape evaluation

Transfection or functional efficacy testing

Cytotoxicity and hemolysis analysis

Receptor-specific targeting validation

Deliverable:Comprehensive in vitro data package

5

in vivo Validation (Optional)

Biodistribution and organ-targeting studies

Pharmacokinetics (PK) and pharmacodynamics (PD) evaluation

mRNA expression or gene-silencing performance assessment

Safety and immunogenicity profiling

Deliverable: in vivo data report and recommended next steps

6

Optimization & Scale-Up Feasibility

Peptide sequence refinement

Enhanced targeting or delivery efficiency

Manufacturability and scalability assessment

Preclinical package preparation

Therapeutic Applications

Our platform is engineered to support the next generation of genetic medicines and precision therapeutics.

Antisense and siRNA Therapeutics

Enhance Cellular Uptake: CPP–ASO and CPP–siRNA conjugates efficiently cross cellular membranes to overcome poor intrinsic permeability.

Improve Tissue Targeting: Targeting peptides (e.g., RGD, Angiopep-2) direct oligonucleotides to tumors, CNS, liver, or muscle tissues.

Increase Bioavailability: Peptide conjugation protects ASOs and siRNAs from nuclease degradation, improving systemic stability and exposure.

Facilitate Endosomal Escape: Fusogenic peptides (e.g., INF7, GALA) promote cytosolic release, enhancing gene-silencing potency.

mRNA and RNA-Based Therapeutics

Enable Efficient Cytosolic Delivery: Peptide-based carriers promote rapid intracellular transport of mRNA beyond endosomal sequestration.

Enhance Expression Efficiency: Optimized CPP and fusogenic modules maximize mRNA translation by improving cytoplasmic availability.

Improve Tissue Selectivity: Targeting peptides enable organ- or cell-specific delivery beyond liver-dominant LNP systems.

Increase Stability and Safety: Fully synthetic peptide systems reduce immunogenicity and improve formulation stability.

CRISPR and Gene Editing Therapeutics

Support RNP Delivery: CPP-based systems enable direct delivery of CRISPR-Cas RNPs without viral vectors.

Improve Editing Efficiency: Enhanced endosomal escape increases nuclear access and genome-editing outcomes.

Reduce Off-Target Effects: Targeted peptide delivery limits systemic exposure and improves tissue precision.

Enable Transient Expression: Non-viral peptide systems support controlled, transient gene editing with improved safety profiles.

Oncology and Precision Cancer Therapy

Enhance Tumor Targeting: Tumor-homing and tumor-penetrating peptides (e.g., RGD, iRGD, LyP-1) selectively accumulate in cancer tissues.

Improve Tumor Penetration: Peptides enable deep penetration into solid tumors and dense tumor microenvironments.

Enable Microenvironment-Responsive Delivery: Enzyme- or pH-responsive peptides activate payload release within tumors.

Reduce Systemic Toxicity: Targeted peptide delivery minimizes off-target exposure while enhancing therapeutic index.

Central Nervous System (CNS) and BBB Delivery

Facilitate BBB Transport: BBB-shuttle peptides (e.g., Angiopep-2, TfR-binding peptides) enable transcytosis across the blood–brain barrier.

Enable Intracellular Delivery: CPP modules support cytosolic delivery of RNA and proteins in neuronal and glial cells.

Improve CNS Bioavailability: Peptide-mediated transport increases brain exposure compared to conventional delivery systems.

Support Diverse Modalities: Compatible with RNA therapeutics, gene-editing cargos, and protein-based treatments.

Protein and Enzyme Replacement Therapies

Enable Cytosolic Protein Delivery: CPPs transport functional proteins and enzymes directly into the cytoplasm.

Overcome Endosomal Trapping: Fusogenic peptides promote intracellular release of biologics.

Expand Therapeutic Scope: Enables treatment of intracellular targets inaccessible to conventional biologics.

Improve Functional Outcomes: Enhanced intracellular delivery increases enzymatic activity and therapeutic efficacy.

Delivery Platform Partnerships

Collaborate with us to unlock next-generation delivery solutions for RNA therapeutics, gene editing, protein biologics, and targeted small-molecule therapies. Our peptide-based delivery platform is designed for flexible integration — whether you need custom peptide engineering, delivery optimization, or full program co-development.

We work with biotechnology companies, pharmaceutical partners, and academic innovators to accelerate therapeutic development from concept to IND and beyond. With modular design, scalable manufacturing, and deep delivery expertise, our platform can be seamlessly adapted to diverse therapeutic pipelines. Partner with our team to design and deploy customized peptide-based delivery solutions for your therapeutic programs.

FAQs

Our platform is compatible with a wide range of modalities, including:mRNA and self-amplifying RNAsiRNA, ASO, and DNA oligonucleotidesCRISPR RNPs and gene-editing complexesRecombinant proteins, enzymes, and peptidesSmall molecules requiring targeted or intracellular delivery

Yes.Our CPP-based and fusogenic platforms are highly efficient for delivering Cas9 RNPs into the cytosol with improved endosomal escape.

Yes.We provide AI-guided sequence design, module selection, optimization, and synthesis for:CPPsTargeting ligandsFusogenic peptidesSelf-assembling peptide scaffoldsPeptide conjugates for LNP or polymer systems

Absolutely.We provide:BBB-penetrating peptides (e.g., TfR, Angiopep-2 analogs)Tumor-targeting & penetrating peptides (RGD, iRGD, NGR, LyP-1)MMP-responsive activation motifs

We provide:Research-grade peptide & nanoparticle manufacturingTech transfer to GMP-certified partnersScale-up guidance